CV Technologies Inc. Release: World's Top Cancer Research Body Sponsors Landmark COLD-FX(R) Trial
Published: Nov 17, 2008
EDMONTON, ALBERTA--(Marketwire - November 17, 2008) - CV Technologies Inc. (TSX: CVQ) today announced that COLD-FX® will be the focus of a landmark U.S. National Cancer Institute (NCI) sponsored trial involving chronic lymphocytic leukemia patients - the first time the natural medicine will be part of a clinical study associated with cancer. The NCI, part of the U.S. National Institutes of Health, is the world's most prestigious cancer research body. The trial will be conducted by American cancer and infectious diseases experts at Wake Forest University School of Medicine in Winston-Salem, North Carolina.